Septo-optic dysplasia

Septo-optic dysplasia is a disorder of early brain development. Although its signs and symptoms vary, this condition is traditionally defined by three characteristic features: underdevelopment (hypoplasia) of the optic nerves, abnormal formation of structures along the midline of the brain, and pituitary hypoplasia.

The first major feature, optic nerve hypoplasia, is the underdevelopment of the optic nerves, which carry visual information from the eyes to the brain. In affected individuals, the optic nerves are abnormally small and make fewer connections than usual between the eyes and the brain. As a result, people with optic nerve hypoplasia have impaired vision in one or both eyes. Optic nerve hypoplasia can also be associated with unusual side-to-side eye movements (nystagmus) and other eye abnormalities.

The second characteristic feature of septo-optic dysplasia is the abnormal development of structures separating the right and left halves of the brain. These structures include the corpus callosum, which is a band of tissue that connects the two halves of the brain, and the septum pellucidum, which separates the fluid-filled spaces called ventricles in the brain. In the early stages of brain development, these structures may form abnormally or fail to develop at all. Depending on which structures are affected, abnormal brain development can lead to intellectual disability and other neurological problems.

The third major feature of this disorder is pituitary hypoplasia. The pituitary is a gland at the base of the brain that produces several hormones. These hormones help control growth, reproduction, and other critical body functions. Underdevelopment of the pituitary can lead to a shortage (deficiency) of many essential hormones. Most commonly, pituitary hypoplasia causes growth hormone deficiency, which results in slow growth and unusually short stature. Severe cases cause panhypopituitarism, a condition in which the pituitary produces no hormones. Panhypopituitarism is associated with slow growth, low blood sugar (hypoglycemia), genital abnormalities, and problems with sexual development.

The signs and symptoms of septo-optic dysplasia can vary significantly. Some researchers suggest that septo-optic dysplasia should actually be considered a group of related conditions rather than a single disorder. About one-third of people diagnosed with septo-optic dysplasia have all three major features; most affected individuals have two of the major features. In rare cases, septo-optic dysplasia is associated with additional signs and symptoms, including recurrent seizures (epilepsy), delayed development, and abnormal movements.

Frequency

Septo-optic dysplasia has a reported incidence of 1 in 10,000 newborns.
Causes
In most cases of septo-optic dysplasia, the cause of the disorder is unknown. Researchers suspect that a combination of genetic and environmental factors may play a role in causing this disorder. Proposed environmental risk factors include viral infections, specific medications, and a disruption in blood flow to certain areas of the brain during critical periods of development.

At least three genes have been associated with septo-optic dysplasia, although mutations in these genes appear to be rare causes of this disorder. The three genes, HESX1, OTX2, and SOX2, all play important roles in embryonic development. In particular, they are essential for the formation of the eyes, the pituitary gland, and structures at the front of the brain (the forebrain) such as the optic nerves. Mutations in any of these genes disrupt the early development of these structures, which leads to the major features of septo-optic dysplasia.

Researchers are looking for additional genetic changes that contribute to septo-optic dysplasia.

Inheritance Pattern
Septo-optic dysplasia is usually sporadic, which means that the condition typically occurs in people with no history of the disorder in their family.

Less commonly, septo-optic dysplasia has been found to run in families. Most familial cases appear to have an autosomal recessive pattern of inheritance, which means that both copies of an associated gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition. In a few affected families, the disorder has had an autosomal dominant pattern of inheritance, which means one copy of an altered gene in each cell is sufficient to cause the condition.

Other Names for This Condition
- De Morsier syndrome
- septooptic dysplasia
- SOD

Diagnosis & Management
Genetic Testing Information
- What is genetic testing? /primer/testing/genetictesting
Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22septo-optic+dysplasia%22

Other Diagnosis and Management Resources

- MedlinePlus Encyclopedia: Growth Hormone Deficiency
  https://medlineplus.gov/ency/article/001176.htm
- MedlinePlus Encyclopedia: Hypopituitarism
  https://medlineplus.gov/ency/article/000343.htm

Additional Information & Resources

Health Information from MedlinePlus

- Encyclopedia: Growth Hormone Deficiency
  https://medlineplus.gov/ency/article/001176.htm
- Encyclopedia: Hypopituitarism
  https://medlineplus.gov/ency/article/000343.htm
- Health Topic: Brain Malformations
  https://medlineplus.gov/brainmalformations.html
- Health Topic: Optic Nerve Disorders
  https://medlineplus.gov/opticnervedisorders.html
- Health Topic: Vision Impairment and Blindness
  https://medlineplus.gov/visionimpairmentandblindness.html

Genetic and Rare Diseases Information Center

- Septo-optic dysplasia spectrum

Additional NIH Resources

- National Institute of Neurological Disorders and Stroke
  https://www.ninds.nih.gov/Disorders/All-Disorders/Septo-optic-dysplasia-Information-Page

Educational Resources

- MalaCards: septooptic dysplasia
  https://www.malacards.org/card/septooptic_dysplasia
- Orphanet: Septo-optic dysplasia spectrum
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=3157
- The MAGIC Foundation: Panhypopituitarism
  https://www.magicfoundation.org/Growth-Disorders/Panhypopituitarism/
Patient Support and Advocacy Resources

- American Foundation for the Blind
  https://www.afb.org/
- National Federation of the Blind
  https://www.nfb.org/
- Resource list from the University of Kansas Medical Center
  http://www.kumc.edu/gec/support/visual.html
- The MAGIC Foundation
  https://www.magicfoundation.org/Growth-Disorders/Septo-Optic-Dysplasia/

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Septo-Optic+Dysplasia%5BMAJR%
  5D%29+AND+%28%28septo-optic+dysplasia%5BTA%5D%29+OR+%28septo-
  optic+dysplasia%5BTA%5D%29+OR+%28de+Morsier+syndrome%5BTA
  5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last
  +1800+days%22%5Bda%5D

Catalog of Genes and Diseases from OMIM

- SEPTOOPTIC DYSPLASIA
  http://omim.org/entry/182230

Sources for This Summary

- Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Mårtensson IL, Toresson
  H, Fox M, Wales JK, Hindmarsh PC, Krauss S, Beddington RS, Robinson IC. Mutations in the
  homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9620767
- Dattani MT, Robinson IC. HESX1 and Septo-Optic Dysplasia. Rev Endocr Metab Disord. 2002 Dec;
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12424431
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17587179
- Kelberman D, Dattani MT. Septo-optic dysplasia - novel insights into the aetiology. Horm Res. 2008;
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18259104
  Haufs N, Krude H, Shalet SM, Dattani MT. HESX1 mutations are an uncommon cause of septooptic
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17148560
- Miller SP, Shevell MI, Patenaude Y, Poulin C, O'Gorman AM. Septo-optic dysplasia plus: a
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10762523
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16423603

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12519827

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11136712

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19623216 
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987262/


Reviewed: March 2010
Published: June 11, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services